Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT00003897 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Start date: May 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.

NCT ID: NCT00003895 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Start date: April 1999
Phase: Phase 2
Study type: Interventional

This randomized pilot phase II trial studies how well vaccine therapy works in treating human leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT00003828 Completed - Melanoma (Skin) Clinical Trials

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Start date: May 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating patients who have stage IV melanoma that has been previously treated.

NCT ID: NCT00003802 Completed - Melanoma (Skin) Clinical Trials

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Start date: February 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have metastatic skin or eye melanoma.

NCT ID: NCT00003792 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: April 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.

NCT ID: NCT00003789 Completed - Recurrent Melanoma Clinical Trials

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

Start date: March 1999
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Heating melphalan to several degrees above body temperature and infusing it only to the area around the tumor may kill more tumor cells. It is not yet known whether combining melphalan with tumor necrosis factor is more effective than melphalan alone in treating melanoma.

NCT ID: NCT00003665 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Start date: April 1999
Phase: Phase 1
Study type: Interventional

Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.

NCT ID: NCT00003647 Completed - Stage IV Melanoma Clinical Trials

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: July 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.

NCT ID: NCT00003646 Completed - Stage IV Melanoma Clinical Trials

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: August 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

NCT ID: NCT00003601 Completed - Melanoma (Skin) Clinical Trials

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Start date: February 23, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tretinoin and/or fenretinide may be an effective way to prevent the recurrence or further development of dysplastic nevus syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of tretinoin with or without fenretinide in treating patients with dysplastic nevus syndrome.